Please assess the completion status of the following clinical trial:

Trial Title: Phase III Study to Assess the Long Term Efficacy, Carry-over Effect and Safety of 300 IR Sublingual Immunotherapy Tablets

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female outpatients aged 18 to 50 years~* Grass pollen-related allergic rhinoconjunctivitis for at least the last two pollen seasons~* Positive SPT and specific IgE values of at least Class 2 for grass pollen allergens~* A score of greater than or equal to 12 out of a possible 18 on the Retrospective Rhinoconjunctivitis Total Symptom Score (RRTSS)~Exclusion Criteria:~* Patients with symptoms of rhinoconjunctivitis during the grass pollen season due to sensitisation to allergens other than grass pollen must not be included. Patients must be asymptomatic to all other allergens during the grass pollen season. Patients who have allergic rhinitis due to perennial allergen may not be included.~* Asthma requiring treatment other than beta-2 inhaled agonists.~* Patients who have received any desensitisation treatment for grass pollen or with any other allergen within the previous 5 years.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- 300 IR (4M) (Type: EXPERIMENTAL): 300 IR grass pollen allergen extract tablet, treatment starting 4 months before the pollen season
- 300 IR (2M) (Type: EXPERIMENTAL): 300 IR grass pollen allergen extract tablet, treatment starting 2 months before the pollen season
- Placebo (Type: PLACEBO_COMPARATOR): Placebo tablet

Based on this trial design, predict the completion outcome and termination type (if applicable).